This is our first report on Illumina, a well-known provider of sequencing and array-based solutions for genetic and genomic analysis. The company had a great quarter with growth in revenue on part with Wall Street expectations in spite of macroeconomic challenges. In the quarter, Illumina saw fantastic customer response to the recently launched NovaSeq X Series. The company shipped 65 NovaSeq 6000 and the manufacturing scaling is proceeding well. It also launched the first-ever CE-marked and FDA ....
